# Stage 4: Revision Summary

**Date:** 2026-06-03
**Status:** COMPLETED

---

## Major Revisions Addressed

### 1. Statistical Significance Tests ✓

**Added:**
- Table II: Factor IC Statistics with Significance Tests
  - t-statistics, p-values, 95% confidence intervals
  - Statistical significance indicators (α=0.05)

- Table III: Bootstrap Confidence Intervals
  - 95% CI for Total Return, Annual Return, Sharpe Ratio
  - 1,000 bootstrap iterations

- Section 5.5: Strategy vs Benchmark Comparison
  - Paired t-test results (t=0.475, p=0.464)
  - Transparent reporting of non-significance

**Key Findings:**
- amihud_illiq: Significant positive IC (p=0.013)
- reversal_1m, rsi_14, macd_hist: Significant negative IC (p<0.05)
- momentum factors: Positive but not significant (p>0.05)
- Strategy vs benchmark: Excess return +20.56%, but not statistically significant

### 2. Reproducibility Details ✓

**Added in Section 5.1:**
- Reproducibility Parameters table
- Stock selection criteria
- Look-ahead bias acknowledgment
- Walk-forward methodology description

**Added in Section 4.5:**
- Algorithm 1: IC-Weighted Multi-Factor Strategy
- Complete pseudocode for strategy execution
- Time complexity analysis: O(S × F × T)

### 3. Expanded Experimental Analysis ✓

**Added:**
- Section 5.3: Factor IC Analysis with Significance Tests
- Section 5.4: Bootstrap Confidence Intervals
- Section 5.5: Strategy vs Benchmark Comparison
- Statistical interpretation of results

**Acknowledged Limitations:**
- Sample size (11 stocks) limits statistical power
- Wide confidence intervals reflect uncertainty
- Look-ahead bias in weight determination

### 4. Reference Cleanup ✓

**Removed:**
- Orphan references [1], [2], [6], [7], [9]-[13], [16], [17], [19], [20], [22]-[26] from previous version

**Renumbered:**
- [1] Fama & French (1993)
- [2] Fama & French (2015)
- [3] Gu, Kelly, Xiu (2020)
- [4] Liu & Ma (2022)
- [5] Liu, Stambaugh, Yuan (2019)
- [6] Rosenberg (1974)
- [7] MSCI (2023)

**Updated Citations:**
- All text citations now correctly reference new numbering

---

## Issues Not Addressed

### Critical: Expanded Dataset
**Status:** NOT ADDRESSED
**Reason:** AKShare API failed to return data for any stocks during testing
**Mitigation:**
- Transparent acknowledgment of sample size limitation
- Bootstrap confidence intervals to quantify uncertainty
- Clear statement that results are preliminary/pilot study

**Recommendation for Future Work:**
- Obtain licensed data from Bloomberg, Wind, or Tushare Pro
- Target 50-100 CSI 300 stocks
- Implement true walk-forward with 2020-2021 training, 2022-2024 testing

### Walk-Forward Out-of-Sample Testing
**Status:** DESCRIBED BUT NOT IMPLEMENTED
**Reason:** Insufficient data from API
**Mitigation:**
- Methodology described in Section 5.1
- Limitations acknowledged in Section 5.5
- Future work identified in Section 7.3

---

## Paper Statistics

| Metric | Before Revision | After revision |
|--------|-----------------|----------------|
| Word count | ~4,200 | ~4,800 |
| Tables | 2 | 4 |
| Statistical tests | 0 | 6 |
| References | 27 (many orphan) | 7 (all cited) |
| Algorithm pseudocode | No | Yes |
| Confidence intervals | No | Yes |
| Significance tests | No | Yes |

---

## Academic Pipeline Progress

| Stage | Status |
|-------|--------|
| 2.5 INTEGRITY | ✓ COMPLETED |
| 3 REVIEW | ✓ COMPLETED |
| 4 REVISE | ✓ **COMPLETED** |
| 4.5 RE-REVIEW | ⏳ Pending |
| 5 FINALIZE | ⏳ Pending |

---

## Next Steps

1. **Stage 4.5: RE-REVIEW** - Verify revisions adequately address reviewer feedback
2. **Stage 5: FINALIZE** - Final formatting for IEEE Access submission
3. **Post-Acceptance:** Obtain licensed CSI 300 data for expanded validation

---

## Files Generated/Modified

| File | Status |
|------|--------|
| paper_english.md | Modified - Added statistics, cleaned references |
| run_enhanced_backtest.py | Created - Walk-forward testing (API failed) |
| run_statistical_analysis.py | Created - Statistical tests |

---

*Revision completed following academic peer review standards*
